Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon Medical to collaborate on bird flu research

Aethlon Medical : 27 September, 2007  (New Product)
Aethlon Medical is to begin research studies to test the in vitro effectiveness of the Aethlon Hemopurifier to capture H5N1 Avian Influenza.

Testing of the Hemopurifier will be conducted through collaborations with researchers at Commonwealth Biotechnologies and Battelle Biomedical Research Center.

Both organizations are approved by the Department of Health and Human Services (HHS) under the Select Agent Programs of the Centers for Disease Control and Prevention (CDC) and the Animal and Plant Health Inspection Service (APHIS) to carry out studies on highly pathogenic avian influenza.

At present, H5N1 Avian Influenza does not pass efficiently in human-to-human transmissions. However, it is feared the virus, whose mortality rate in infected humans exceeds 60 percent, will evolve to spark global pandemic. Scientific publications attribute high mortality rates to evidence of H5N1 spreading through the bloodstream to organs and other regions of the body not normally affected by influenza viruses.

'We are grateful to colleagues at Commonwealth and Battelle for allowing us the opportunity to demonstrate the ability of our Hemopurifier to capture highly pathogenic forms of influenza, including H5N1,' stated Aethlon chairman and CEO, James A Joyce. 'By targeting the systemic infection occuring in the blood of H5N1 patients, the Hemopurifier would be positioned to fill an significant void not addressed by other therapeutics.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo